國家衛生研究院 NHRI:Item 3990099045/10948
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 877643      Online Users : 1390
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10948


    Title: Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes
    Authors: Tseng, CH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: BACKGROUND: Metformin, an antidiabetic drug, is associated with decreased cancer risk, but its effect on skin cancer is unknown. OBJECTIVE: To evaluate skin cancer risk associated with metformin use. METHODS: Matched pairs of 16237 ever and never metformin users were retrospectively enrolled from patients with new-onset type 2 diabetes diagnosed between 1999 and 2005 from Taiwan's National Health Insurance database, and followed until December 31, 2011. Hazard ratios (HRs) were estimated using Cox regression weighted for propensity scores. RESULTS: Skin cancer incidence was 45.59 and 83.90 per 100,000 person-years in ever and never users, respectively (HR 0.540, 95% confidence interval: 0.357-0.819). In ever users, the HRs (95% confidence intervals) for the first (<21.00 months), second (21.00-45.83 months), and third (>45.83 months) cumulative duration tertiles were 0.817 (0.448-1.489), 0.844 (0.504-1.412), and 0.114 (0.036-0.364), respectively; and 1.006 (0.579-1.748), 0.578 (0.317-1.051), and 0.229 (0.099-0.530), respectively, for the first, second, and third cumulative dose tertiles. HRs were 0.523 (0.175-1.562) for melanoma and 0.496 (0.319-0.772) for non-melanoma skin cancer. LIMITATIONS: Few patients with skin cancer and lack of information on ultraviolet exposure and tumor histopathology. CONCLUSION: Metformin use is associated with decreased skin cancer risk.
    Date: 2018-04
    Relation: Journal of the American Academy of Dermatology. 2018 Apr;78(4):694-700.
    Link to: http://dx.doi.org/10.1016/j.jaad.2017.12.016
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0190-9622&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000427404200013
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85041694703
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB29246826.pdf444KbAdobe PDF294View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback